Evidence map›Paper›PMID 42604326›Full record

ArticleJTCVS open2026

Cumulative high-risk surgical and pathologic features predict recurrence after resection of early-stage node-negative non-small cell lung cancer.

Fatemehsadat Pezeshkian, Emanuele Mazzola, Justin S Heidel, José A Rodriguez Zamboni, Andes Wong, Yue Xie, Chandana Adhikarla, Antonio Coppolino, Matthew M Rochefort, Scott J Swanson and 2 more

Abstract read
In one paragraph

Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fatemehsadat PezeshkianDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Emanuele MazzolaDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Mass.
Justin S HeidelDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
José A Rodriguez ZamboniDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Andes WongHarvard Medical School, Boston, Mass.
Yue XieDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Mass.
Chandana AdhikarlaDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Antonio CoppolinoDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Matthew M RochefortDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Scott J SwansonDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Michael T JaklitschDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.
Paula A Ugalde FigueroaDivision of Thoracic Surgery, Mass General Brigham, Boston, Mass.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Despite curative resection, recurrence remains a clinically relevant problem in patients with early-stage non-small cell lung cancer (NSCLC). Although several high-risk features have been individually associated with adverse outcomes, their cumulative prognostic influence remains unclear. Methods: Patients with NSCLC undergoing curative-intent resection between 2017 and 2024 were identified from a prospective institutional database. Inclusion criteria were solid tumors with size <4 cm, pN0 disease, and R0 resection with documented spread through air spaces status. High-risk features included nonanatomic resection, poorly/undifferentiated grade, lymphovascular invasion (LVI), visceral pleural invasion (VPI), incomplete lymphadenectomy (<3N2 and <1N1 stations), and spread through air spaces positivity. Cox proportional hazards modeling was used to quantify the association of high-risk features and 5-year recurrence-free survival, and a nomogram was constructed to estimate cumulative recurrence risk. Results: Of the 497 patients included, anatomic resection was performed in 268 (53.9%) patients and complete lymphadenectomy was achieved in 126 (25.4%). Over a median 30-month follow-up (interquartile range, 13-49 months), 50 patients (10.1%) developed recurrence. LVI (hazard ratio [HR], 3.7; 95% CI, 2-7; Conclusions: A multifactorial nomogram integrating high-risk pathologic features to estimate recurrence risk in early-stage NSCLC was developed. This model suggests that recurrence risk in early-stage NSCLC may be driven by the cumulative burden of high-risk surgical and pathologic features rather than isolated factors, providing a clinically applicable framework for postoperative risk stratification. External validation and integration into clinical decision-making frameworks are warranted.

Indexed as

early-stage lung cancerhigh-risk recurrence featuresnomogramnon–small cell lung cancerrecurrence-free survival

Identifiers

PMID42604326
PMCPMC13477078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.